Group 1: Dutch Bros - Dutch Bros (NYSE: BROS) is recommended for purchase now and again in the $40s by Jim Cramer [1] - RBC Capital analyst Logan Reich maintains an Outperform rating on Dutch Bros with a price target of $85 [1] - Dutch Bros shares fell 1.4% to settle at $53.36 [5] Group 2: American Bitcoin Corp - American Bitcoin Corp (NASDAQ: ABTC) is considered a "total spec" by Jim Cramer [1] - American Bitcoin recently appointed KPMG as its new auditor [1] - American Bitcoin shares fell 4.3% to close at $6.69 [5] Group 3: Recursion Pharmaceuticals - Recursion Pharmaceuticals (NASDAQ: RXRX) is viewed negatively, with Cramer stating a need for improvement before investment [2] - The company reported second-quarter revenue of $19.22 million, exceeding analyst estimates of $16.23 million [2] - Recursion reported a second-quarter loss of 41 cents per share, missing forecasts of a loss of 34 cents per share [2] - Recursion Pharmaceuticals shares declined 5.1% to settle at $4.63 [5] Group 4: Republic Services - Republic Services, Inc. (NYSE: RSG) requires a bounce according to Jim Cramer [3] - Barclays analyst William Grippin initiated coverage on Republic Services with an Equal-Weight rating and a price target of $240 [3] - Republic Services shares fell 0.2% to close at $226.86 [5]

Group 1: BigBear.ai Overview - BigBear.ai has experienced significant stock price growth, with shares up over 70% year to date in 2025 [1] - The company currently has a market capitalization of approximately $2.9 billion [5] - BigBear.ai reported an 18% year-over-year revenue decline in Q2 2025 and has not achieved positive free cash flow [5][6] Group 2: Diebold Nixdorf Analysis - Diebold Nixdorf has a market capitalization of just over $2 billion, which is lower than BigBear.ai's [5] - The company serves major global financial institutions and retailers, providing cash management solutions and software applications [4] - Diebold Nixdorf's revenue fell only 2.6% year-over-year in Q2 2025, and it reported a 9% revenue increase from Q1 2025 [5] - The company ended Q2 with a backlog of around $980 million and has generated three consecutive quarters of positive free cash flow [6] - Diebold Nixdorf's price-to-sales ratio is significantly lower at 0.59 compared to BigBear.ai's 14.4 [6] - The company is also focused on AI, with its Vynamic Smart Vision technology recently winning an award [7] Group 3: Recursion Pharmaceuticals Insights - Recursion Pharmaceuticals has a smaller market capitalization compared to BigBear.ai, but its AI-driven drug discovery approach is seen as a potential game changer [8][10] - The company is currently reliant on collaboration agreements for revenue, with major partners including Roche, Sanofi, Bayer, and Merck KgAA [12] - Recursion has three experimental cancer therapies in development and is exploring treatments for rare genetic diseases [11] - The company has attracted significant interest from Nvidia, which owns approximately 7.7 million shares of Recursion [12] - There is optimism that Recursion's innovative approach could lead to a higher valuation than BigBear.ai in five years if its pipeline performs well [13]

It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX), you’re greeted with a clear message: Barchart’s Technical Opinion indicator rates RXRX stock as a 72% Strong Sell. From an empirical perspective, suggesting a contrarian position would place you on shaky ground. Since the start of the year, RXRX stock is down nearly 28%, which in many respects is understandable given the uncertainties associated with the broader healthcare ecosystem ...

Core Insights - Recursion Pharmaceuticals, Inc. is leveraging artificial intelligence and machine learning to enhance drug discovery, particularly in rare diseases and oncology [1] - The company achieved a significant milestone with a $12.5 million payment from Rallybio for the advancement of its investigational drug REV102 [2] - Recent technological advancements include the launch of Boltz-2, developed in collaboration with MIT, to improve predictions for small molecule–protein interactions [3] Company Developments - Recursion's pipeline includes six lead candidates, with four focused on oncology and two on rare diseases, with key assets like REC-aK7 and REC-4881 progressing in clinical trials [4] - The company has made strides in regulatory progress for rare disease assets and has expanded collaborations with institutions such as MIT, Tempus, and HealthVerity [5] - Investor engagement is increasing, highlighted by presentations at events like Needham's healthcare session in New York [5]

Group 1 - Needham maintains a "Buy" rating for Recursion Pharmaceuticals, with a target price of $8, indicating a potential upside of 68% from the current price of $4.77 [1] - Recursion Pharmaceuticals is recognized as one of the top 12 penny stocks favored by Wall Street hedge funds, highlighting its strong market position [1] - The company is leveraging AI technology in drug development, positioning itself as a leader in the field with proprietary datasets [1][2] Group 2 - Gil Blum, a senior analyst at Needham, emphasizes that Recursion has taken significant steps to extend its financial runway, focusing on its flagship product pipeline, which is expected to sustain cash flow until Q4 2027 [2] - The optimistic outlook for Recursion is supported by anticipated clinical results in the next 12 to 18 months, particularly for the solid tumor drug REC-617 [2] - Other Wall Street firms, such as Morgan Stanley and Bank of America, have a more cautious stance, maintaining "Hold" ratings with target prices of $4.8 and $8, respectively [3] Group 3 - Recursion Pharmaceuticals is a clinical-stage biotech company utilizing cutting-edge AI technology to decode biology and chemistry for accelerated drug development [4] - The company's Recursion Operating System (Recursion OS) integrates high-throughput biological experiments, imaging, and machine learning into a unified platform for drug discovery [4][5] - Recent advancements include the BioHive-2 AI supercomputing cluster and acquisitions that enhance its capabilities in biological and chemical modeling [5] Group 4 - The integration of AI in healthcare is projected to grow significantly, with the market value expected to reach $189.9 billion by 2030, reflecting a CAGR of 43.7% [7] - AI is anticipated to optimize various medical processes, including drug discovery, medical imaging, and precision medicine, thereby reducing innovation cycles and improving patient outcomes [7] - The convergence of AI and pharmaceuticals is seen as a revolutionary trend, with potential breakthroughs in drug design and clinical trials expected in the near future [6]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, Needham retained its Buy rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), maintaining the price target at $8. Gil Blum from Needham reaffirmed the rating on RXRX due to various factors, pointing out the company’s strong position in the AI-driven drug discovery sector. Being a leader in this space, the company is backed by its extensive and proprietary dataset. ...

Group 1 - The session features Recursion with Co-Founder and CEO Chris Gibson, along with Chief R&D Officer and Chief Commercial Officer Najat Khan [2]

Question-and-Answer SessionSo maybe talk about the business from the perspective of the technology platform, the clinical pipeline and maybe just the overall strategy and business model to get us started?Ben TaylorCFO & President of Recursion UK Sure. Yes, a couple of important points there. So Recursion has been around for about 13 years, and the underlying mission of the company has, throughout that period, been to look at why drugs fail and try and find a better way to create a predictive model around th ...

Core View - Nvidia's portfolio stocks experienced a significant decline, indicating potential market volatility and investor sentiment shifts [1] Group 1: Stock Performance - CoreWeave (CRWV.US) dropped over 9% [1] - Arm Holdings (ARM.US) fell more than 4% [1] - Applied Digital Corporation (APLD.US) decreased by over 4% [1] - Nebius (NBIS.US) declined more than 5% [1] - Recursion Pharmaceuticals (RXRX.US) saw a drop of over 2% [1]

Core View - Nvidia's portfolio stocks experienced a significant decline, with CoreWeave dropping over 9% and Arm Holdings falling more than 4% [1] Company Performance - CoreWeave (CRWV.US) saw a decline of over 9% [1] - Arm Holdings (ARM.US) decreased by more than 4% [1] - Applied Digital Corporation (APLD.US) fell by over 4% [1] - Nebius (NBIS.US) dropped more than 5% [1] - Recursion Pharmaceuticals (RXRX.US) experienced a decline of over 2% [1]